Abstract Library

#4139 Characterisation of new biomarkers from patients with neuroendocrine cancer using liquid biopsy methods

Introduction: Neuroendocrine tumors originate from neuroendocrine cells. Clinicians diagnose and track these tumors not only but also by analysing patients' blood for biomarkers. Including liquid biopsy in early detection and monitoring can improve patient outcomes.

Conference:

Presenting Author:

Authors: Pachnikova G, Jann H, Tacke F, Keilholz U,

Keywords: liquid biopsy, circulating tumor cells, cell-free DNA, neuroendocrine tumor, case study, copy number variations,

#3387 High tissue expression of Flt3L is linked to higher infiltration of immune cells in patients with high-grade GEP-NEN

Introduction: The clinical management of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) remains challenging due to disease heterogeneity. We have recently shown that mRNA expression of the immunostimulatory cytokine FMS-like tyrosine kinase 3 ligand (Flt3L) in tumor tissue is a prognostic biomarker in high-grade GEP-NEN patients. However, a direct link between Flt3L expression and the presence of proinflammatory immune cells in the tumor microenvironment (TME) of GEP-NEN is still missing.

Conference:

Presenting Author: Werner W

Authors: Werner W, Detjen K, Bruneau A, Wiedenmann B, Tacke F,

Keywords: NET, Flt3L, DC, dendritic cell, biomarker, immune response, immune microenvironment,

#3259 Treatment outcomes of patients with G3 neuroendocrine neoplasms

Introduction: Extrapulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia that are associated with a limited prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Jann H, Wiedenmann B, Tacke F, Roderburg C,

Keywords: NEN G3, chemotherapy, Cisplatin, Carboplatin,

#3244 Efficacy and safety of immune checkpoint inhibitors in patients with neuroendocrine neoplasia: Report of a case series from a large tertiary centre

Introduction: Immune checkpoint inhibitors (ICI) have changed our view on how to treat cancer. Despite their approved treatment of many different cancers, efficacy of ICI in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocrine tumors (NET) and carcinomas (NEC) are based on surgery, tumor-targeted medical treatments, peptide guided radioreceptor therapy (PRRT) and locoregional therapies. However, in many patients these treatments lose efficacy over time, and novel therapies are urgently needed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Jann H, Tacke F, Wiedenmann B, Roderburg C,

Keywords: checkpoint inhibitor, neuroendocrine neoplasia, PD-L1,

#3240 miR-29b serum levels are down-regulated in patients with neuroendocrine tumors

Introduction: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Mohr R, Jann H, Geisler L, Tacke F,

Keywords: neuroendocrine tumor, miRNA, miR-29, prognosis, biomarker,